Johnson & Johnson

News

The first targeted drug for a common form of bladder cancer that can be taken at home. J&J's Balversa, has been backed for NHS use.

News

Johnson & Johnson's third attempt to use bankruptcy proceedings to settle lawsuits claiming its talc-based products harmed consumers has failed.

News

New survival data from MARIPOSA for Johnson & Johnson's Rybrevant/Lazcluze combination in lung cancer could spell trouble for AstraZeneca.

News

AstraZeneca will open its sixth R&D centre in China, while J&J announces four new manufacturing facilities in the US in a major reshoring drive.

News

J&J's Tremfya gets a much-anticipated FDA approval for Crohn's disease, which the company thinks will be key to a renewed phase of sales growth.

News

Johnson & Johnson's FcRn inhibitor nipocalimab has been awarded fast-track status by the FDA as a treatment for Sjogren's disease.